Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid.

Ting YangYifan DangBeth OstaszewskiDavid MengelVerena SteffenChristina RabeTobias BittnerDominic M WalshDennis J Selkoe

Published in: Annals of neurology (2019)

Crenezumab lowered CSF oAβ levels in the large majority of treated patients tested. These results support engagement of the principal pathobiological target in AD and identify CSF oAβ as a novel pharmacodynamic biomarker for use in trials of anti-Aβ agents. ANN NEUROL 2019;86:215-224.

Keyphrases

cerebrospinal fluid
newly diagnosed
end stage renal disease
social media
ejection fraction
knee osteoarthritis
clinical trial
chronic kidney disease
study protocol
randomized controlled trial
prognostic factors
cognitive decline
open label